Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.1 put into Wellington says it does not support Bristol-Myers' acquisition of Celgene
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $44.51 -8.9%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
Revenue Growth %: +5.3%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
Revenue Growth %: +5.3%
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) call put ratio 1 call to 1.1 put into Wellington says it does not support Bristol-Myers' acquisition of Celgene (CELG).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- T-Mobile (TMUS) and EQT Announce JV to Acquire Lumos
- Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue
Create E-mail Alert Related Categories
Mergers and Acquisitions, Options, Trader TalkRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
